ArticleClinical research in cardiology : official journal of the German Cardiac Society2025
Impact of age on outcomes after transcatheter tricuspid valve edge-to-edge repair: insights from EuroTR.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06307262 (European Registry of Transcatheter Repair for Tricuspid Regurgitation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAge stratified data regarding symptomatic and survival outcome of patients undergoing transcatheter tricuspid valve edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) are scarce. Aim of this study was to evaluate TR reduction, symptomatic outcomes, and survival following T-TEER stratified by patient age at intervention.
methodsUsing data from the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry, NCT06307262) we investigated the impact of patient age at intervention on procedural TR reduction, clinical outcome according to New York Heart Association (NYHA) class at latest available follow-up and two-year survival as well as two-year survival free from hospitalization for heart failure (HHF).
resultsThe study included 2340 patients divided into four groups according to quartiles of age at intervention (1st quartile: 668 patients [69.9 ± 7.2 years] up to 4th quartile: 561 patients [86.2 ± 2.2 years]). Most common TR etiology in all groups was secondary TR with 83.6%-90.1%. TR reduction from baseline to discharge was similar in all groups (TR ≤2+ 77.3% 1st quartile, 82% 2nd quartile, 79.5% 3rd quartile and 82.8% 4th quartile, p = 0.085). TR severity at follow-up was also comparable (TR ≤2+ 68.1% 1st quartile, 72.1% 2nd quartile, 76.7% 3rd quartile and 73.7% 4th quartile, p = 0.135). Regarding NYHA class patients in all groups benefited equally. Overall two-year survival and two-year survival free from HHF after intervention did not differ between age groups.
conclusionsT-TEER effectively reduces TR in elderly patients. Irrespective of age, patients showed symptomatic benefit and comparable two-year survival free from HHF.
Indexed as
Identifiers
40988005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.